NMD Pharma, a private biotech company developing novel therapies for severe neuromuscular disorders, announced that the first subject has been dosed in a Combined Phase I/IIa clinical trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis.
Myasthenia gravis is an autoimmune neuromuscular disease that causes skeletal muscle weakness due to the defective communication between nerves and muscles.
NMD670 is a small molecule inhibitor of the muscle specific chloride ion channel, ClC-1. Preclinical studies demonstrated that ClC-1 inhibition reduces the inhibitory current and thereby increases muscle membrane excitability and strengthens neuromuscular transmission. This novel treatment approach has shown compelling preclinical safety and efficacy data for Myasthenia Gravis.
The combined Phase I/IIa clinical trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670 in male and female healthy subjects and patients with Myasthenia Gravis.
Photo by Jan Vasek from Jeshoots